ROLE OF CYTOCHROMES P450 IN DRUG-METABOLISM AND HEPATOTOXICITY

被引:158
作者
WATKINS, PB
机构
关键词
D O I
10.1055/s-2008-1040480
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The cytochromes P450 may represent the major metabolic frontier between the environment and the body. The recent discovery of interpatient differences in P450 profile has provided a plausible explantation for heterogeneous dosing requirements for some individual drugs. The heterogeneity in P450 profiles appears to also account for some ''idiosyncratic'' drug reactions, especially hepatotoxicity. An important challenge for the future is the development of safe and noninvasive tests capable of determining patients' P450 profiles. It is likely that such tests will greatly facilitate individualization of dosing of many drugs in the future. In addition, such tests should be useful in identifying patients likely to develop ''idiosyncratic'' toxicity to specific drugs. Finally, it seems likely that interpatient differences in P450 profile may at least in part explain interpatient differences in susceptibility to environmental diseases. For example, it may in the future be possible to identify individuals with P450 profiels that render them susceptible to leukemia from xenobiotics such as benzene. Such individuals could be advised not to work in an environment containing these chemicals or, alternatively, to take a medication which reduces their risk by appropriately altering their P450 profile. Identification and in vitro characterization of human P450s is now well underway and may be largely completed within the next decade. However, studies addressing the clinical significance of interpatient differences in P450 profile, as well as the genetic and nongenetic factors that underlie this heterogeneity, are just beginning. This should remain a rewarding area of research for many years to come.
引用
收藏
页码:235 / 250
页数:16
相关论文
共 176 条
[1]  
ADESNIK M, 1985, CRC CRIT REV BIOCH, V19, P247
[2]   INTERACTION OF ACUTE ETHANOL ADMINISTRATION WITH ACETAMINOPHEN METABOLISM AND TOXICITY IN RATS FED ALCOHOL CHRONICALLY [J].
ALTOMARE, E ;
LEO, MA ;
LIEBER, CS .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1984, 8 (04) :405-408
[3]  
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[4]   HUMAN CDNA-EXPRESSED CYTOCHROME-P450 IA2 - MUTAGEN ACTIVATION AND SUBSTRATE-SPECIFICITY [J].
AOYAMA, T ;
GONZALEZ, FJ ;
GELBOIN, HV .
MOLECULAR CARCINOGENESIS, 1989, 2 (04) :192-198
[5]  
ARGUS MF, 1978, J NATL CANCER I, V61, P441
[6]  
BARBEAU A, 1985, LANCET, V2, P1213
[7]   LIDOCAINE METABOLISM IN HUMAN-LIVER MICROSOMES BY CYTOCHROME-P450IIIA4 [J].
BARGETZI, MJ ;
AOYAMA, T ;
GONZALEZ, FJ ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (05) :521-527
[8]   HUMAN ANTI-ENDOPLASMIC RETICULUM AUTOANTIBODIES APPEARING IN A DRUG-INDUCED HEPATITIS ARE DIRECTED AGAINST A HUMAN-LIVER CYTOCHROME-P-450 THAT HYDROXYLATES THE DRUG [J].
BEAUNE, P ;
DANSETTE, PM ;
MANSUY, D ;
KIFFEL, L ;
FINCK, M ;
AMAR, C ;
LEROUX, JP ;
HOMBERG, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (02) :551-555
[9]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[10]   HERBIVORE-PLANT INTERACTIONS - MIXED-FUNCTION OXIDASES AND SECONDARY PLANT SUBSTANCES [J].
BRATTSTEN, LB ;
WILKINSON, CF ;
EISNER, T .
SCIENCE, 1977, 196 (4296) :1349-1352